Key Points

Introduction
Warfarin and other vitamin K antagonists impair synthesis of the vitamin K-dependent coagulation factors. The most common complication is bleeding, which results from reduction in the vitamin K-dependent procoagulant factors, prothrombin (factor II), factor X, IX, and VII.
Less often, warfarin causes microvascular thrombosis, a complication believed to result primarily from decreased levels of one or both of the vitamin K-dependent natural anticoagulants, protein C (PC) and protein S. 1, 2 The classic picture of 'coumarin necrosis' involves dermal/subdermal tissues predominantly at non-acral sites (e.g., breast, abdomen, thigh, calf, forearms).
1,2
Warfarin therapy has also been implicated in the pathogenesis of venous limb gangrene. and severe PC depletion. 4 Affected patients characteristically have a supratherapeutic international normalized ratio (INR). 4, 5 There are also case reports of warfarin-induced venous limb gangrene complicating metastatic cancer, usually adenocarcinoma. [6] [7] [8] [9] [10] The clinical features and pathogenesis of this
For personal use only. on August 16, 2017 . by guest www.bloodjournal.org From syndrome are obscure, although two reports 7, 8 provided laboratory data (increased TAT to PC activity ratio) suggesting a model of disturbed procoagulant-anticoagulant balance mimicking that seen in HIT/warfarin-induced venous limb ischemia. We now report 10 patients with cancerassociated severe venous limb ischemia/gangrene allowing us to characterize the clinical and laboratory picture. Our study provides further evidence that the pathogenesis of warfarinassociated venous limb ischemia in cancer resembles that seen in HIT. Moreover, patients exhibit a characteristic clinical picture, namely: (a) platelet count rise on heparin, and platelet count fall after stopping heparin (due to recurrent consumptive coagulopathy, i.e., "cancer associated DIC"); (b) supratherapeutic INR secondary to warfarin; and (c) severe venous limb ischemia/gangrene in the limb affected by DVT. Interestingly, most patients were not known to have had cancer at development of limb ischemia, and all patients had metastatic disease when cancer was diagnosed.
Methods and patients
We identified 10 patients with severe venous limb ischemia or gangrene complicating cancer, using two approaches. First, from a list of 1,134 patients from two hospitals affiliated with (k) tumor-associated thrombotic microangiopathy; (l) pulmonary embolism-associated thrombocytopenia; (m) HIV-associated thrombocytopenia; and (n) insufficient information to classify. All charts were reviewed for limb ischemia, either arterial (absent pulses and/or radiological/pathological evidence of artery thrombosis) or venous/microcirculatory (palpable/Doppler-identifiable pulses). In addition, we reviewed whether warfarin treatment was associated with limb ischemia, and all INR values.
Coagulation factors
For 6 patients with venous limb ischemia/gangrene, we tested 52 available plasma samples (range, 4 to 11 samples per patient) for activity levels for the vitamin K-dependent procoagulant blood samples from 20 non-cancer patients with supratherapeutic INRs (≥3.5) on warfarin therapy obtained from a study 11 evaluating coagulation factors measured pre-/post-infusion of prothrombin complex concentrates (PCC) were studied.
HIT antibody testing
We performed the SRA 12, 13 and PF4/heparin IgG-specific enzyme-immunoassay, 14 as described. 
Antiphospholipid antibodies
Platelet count changes during LMWH
We used the Matisse DVT clinical trial database 15 to obtain information on expected platelet count changes in heparin-treated medical patients; we analyzed those patients without active cancer or cancer-related death for whom baseline, day 3, and day 6 platelet counts were available during treatment with therapeutic-dose enoxaparin.
Statistical analysis
Lind and colleagues 16 have shown that the vitamin K-dependent factor concentrations are explanatory factors related linearly to the reciprocal of the INR (1/INR). Accordingly, we used univariate and multivariate linear regression models 17 to fit the coagulation factor data from each of six individuals. We also simultaneously analyzed the data from all patients in a series of mixed-effect regression models with a random intercept to accommodate the serial dependence
For personal use only. on August 16, 2017 . by guest www.bloodjournal.org From in the several responses within individuals. 18 For each factor we determined the proportion of explained variation. 19 We report the explained variation as R 2 for the individual regression models and Ω 2 for the mixed-effect models. 19 Approval for this study was provided by the Hamilton Integrated Research Ethics Board (HiREB) in accordance with the Declaration of Helsinki. Table 1 lists the most likely explanations for thrombocytopenia among the 100 cancer patients investigated for HIT antibodies (in 4 patients, testing for HIT was performed primarily because of thrombosis rather than thrombocytopenia). The three most common diagnoses were septicemia/multi-organ system failure (n=33), postoperative thrombocytopenia (n=24), and cancer-associated DIC (n=17). Severe venous limb ischemia complicating DVT occurred in 10 patients, with 3 patients exhibiting phlegmasia cerulea dolens and 7 patients ultimately developing venous limb gangrene (some of these latter patients had preceding phlegmasia); all 10 patients were classified by investigators' consensus as having cancer-associated DIC. (range, 4 to 6 days). All 9 patients with available platelet count data exhibited substantial platelet count declines (median, 69% [range, 40% to 83%]) after stopping (or reducing the dose of) heparin. All 10 patients exhibited increases in platelet count during one or more treatment courses with UFH or LMWH, including all 6 patients restarted on UFH or LMWH after HIT test results returned negative. The platelet count increases during heparin treatment were substantial and out-of-keeping for medical patients receiving heparin; for example, 9/10 patients (90%) exhibited at least a doubling of platelet count during an approximate one-week course of heparin anticoagulation, whereas only 14/507 (2.8%) patients in the Matisse-DVT trial who received LMWH exhibited a similar platelet count increase during a comparable time period (P<.0001). Additional laboratory features consistent with DIC included hypofibrinogenemia (fibrinogen=0.6 g/L) that recovered during subsequent anticoagulation with danaparoid, and elevated fibrin Ddimer levels (not shown). Data indicating profoundly disturbed procoagulant-anticoagulant balance included greatly elevated TAT levels (86, 77, and 46 ng/mL; normal, <4.2 ng/mL) at a time when PC activity levels were markedly decreased (0.11, 0.10, and 0.05 U/mL, respectively); concomitant FPS levels were mildly reduced or normal (0.58, 0.66, and 0.49
Results
Explanations for thrombocytopenia
Clinical features of cancer-associated venous limb ischemia
Representative cases
For personal use only. on August 16, 2017 . by guest www.bloodjournal.org From U/mL, respectively). Metastatic lung cancer was subsequently diagnosed. Figure 3 summarizes the characteristic clinical profile of the 10 patients identified with cancerassociated severe venous limb ischemia/gangrene. For 8/10 (80%) patients, the diagnosis of cancer was not known or suspected at initial DVT presentation. Adenocarcinoma was identified in 6/7 cases for which pathology was available (the single exception was clear cell carcinoma of the ovary). In all evaluable patients, the platelet count rose during UFH or LMWH treatment, with a fall after stopping heparin. Progression of DVT to severe venous limb ischemia occurred during warfarin treatment associated with an increase in the INR to a supratherapeutic level.
Schematic picture of cancer-associated venous limb ischemia
With resumption of heparin, the platelet count subsequently rose. Interestingly, 2 patients developed an abrupt platelet count fall, and a thrombotic event, when heparin was briefly held to permit biopsy to diagnose cancer (patients 2 and 6; see Table 2 ). The clinical profile summarized in Fig. 3 is distinct and, to our knowledge, represents a novel clinical syndrome. that very low PC activity levels are a feature of both patient groups; indeed, PC activity levels were higher for the patients with venous limb ischemia than in the controls (P=.024). However, patients with cancer-associated DIC differed from the controls by having significantly greater TAT levels (P=.000018).
FPS levels were only mildly reduced (0.27 U/mL or higher) in some of the cancer patients with venous limb ischemia/gangrene, including 3 who had concomitant PC activity levels that were 0.10 U/mL or less. However, for two other patients (patients 6 and 9, respectively), nadir FPS levels were 0.10 and 0.09 U/mL (with corresponding PC nadirs of 0.07 and 0.08 U/mL, respectively), indicating a possible role for concomitant severe FPS depletion in the pathogenesis of thrombosis in some patients.
Supratherapeutic INR as a surrogate marker for severe PC depletion: regression analyses
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For each of the five patients with sufficient data to fit the models, the univariate analyses consistently demonstrated highly significant associations (P<0.0001) between each explanatory factor (II, VII, X, PC) and the response (1/INR); for the sixth patient for whom we had only four data points, the association between 1/INR and PC was also significant (P=0.01). For PC and 1/INR, the explained variation (Ω 2 ) for 1/INR was 78.8%, which was similar to that seen for factors X (79.6%) and II (78.0%), although not as high as that seen for VII (90.1%).
When factors VII, X and II were considered jointly in multivariate models for each of the five individuals with sufficient data, factor VII retained significance for 4 of the 5 individuals and was associated with the greatest amount of explained variation in 1/INR (the R 2 for VII in individual patients ranged from 88.0% to 98.5%). While PC was highly associated with 1/INR when considered in univariate analyses (the R 2 ranged from 72.6% to 98.0% for the six patients), when adjusted for factors VII, X and II, the partial R 2 associated with PC only ranged from 0.02% to 3.2% across individuals, suggesting that the relation between 1/INR and PC was explained by the association between factors VII, X and II, with the most important of these being factor VII, given the high proportion of variation (~90%) explained by this variable in the presence of the others.
The data from all 6 individuals were then analyzed simultaneously in a series of mixedeffect regression models with a random intercept. When factors VII, X and II were modeled jointly for their effects on 1/INR the proportion of explained variation was 91.8%, with negligible increase when PC was added to the model. In the model with all four factors (VII, X, II, PC), factors VII and X were highly significant (P<.0001) and factor II (P=.1713) and PC (P=0.9822) were not.
For personal use only. on August 16, 2017 . by guest www.bloodjournal.org From These analyses can be interpreted as follows: the strong association between PC and 1/INR is explained by parallel reduction in coagulation factors VII and X, especially the former (VII accounted for ~90% of explained variation). Figure 5A shows a scatter plot of 1/INR vs VII activity, and Figure 5B shows a scatter plot of VII vs PC activity; for this latter plot, the explained variation (Ω 2 ) was 81.9% (P<.0001). These findings indicate that the reduction in factor VII is the major explanation for the INR elevation in such patients. The finding of uncontrolled activation of coagulation (as indicated by the markedly increased TAT levels)
shows that there are sufficient levels of coagulation factors available to produce thrombin despite the low VII levels, perhaps enhanced by the inability of PC to down-regulate thrombin generation.
Despite the very low PC activity levels at the time of warfarin-associated supratherapeutic INR/severe venous limb ischemia, it appeared unlikely that congenital PC deficiency was a contributing factor, based upon the following considerations. First, of the 6 patients shown to have low PC activity levels, 5 had at least one subsequent post-vitamin K plasma sample with PC activity >0.60 U/mL (one patient whose PC activity level rose from 0.02 to only 0.47 U/mL post-vitamin K likely had a residual effect of warfarin, suggested by persisting INR elevation). Fig. 5B shows the very wide variations in PC activity levels, ranging from very low to near-normal/normal, for the 6 patients who underwent testing. Second, none of the 10 cancer patients had a prior history of venous thromboembolism. Third, none of the 10 patients had a known family history of venous thromboembolism.
Antiphospholipid antibody testing
None of seven patients with cancer-associated venous limb ischemia with available serum tested
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Discussion
We report ten patients with cancer-associated venous limb ischemia/gangrene complicating treatment of DVT. In all patients, progression to venous limb ischemia occurred after the heparin was stopped (or dose reduced) and while the patients were continuing to receive warfarin, and occurred in association with a supratherapeutic INR. Moreover, venous limb ischemia occurred in the same limb with recent or concurrent symptomatic DVT. When both lower limbs had DVT, the one with the most recent DVT, or (when onset of bilateral DVT was simultaneous) the one with the greatest burden of thrombosis, progressed to venous limb ischemia/gangrene. This clinical picture thus strongly resembles that of HIT-associated venous limb gangrene associated with warfarin therapy: those patients also develop venous limb ischemic necrosis after stopping heparin and during warfarin therapy associated with a supratherapeutic INR, and those patients also develop acral limb ischemic necrosis in the same limb with a recent DVT. 4 A key difference between the patients in our present report and patients with HITassociated venous limb gangrene is that blood samples from HIT patients contain heparindependent platelet-activating antibodies, whereas the patients with cancer had negative testing for HIT antibodies. Further, the patients we report typically showed a marked increase in platelet count upon resumption of UFH or LMWH therapy, presumably as a result of the anticoagulant slowing the uncontrolled activation of coagulation that is causing platelet consumption. Indeed, it is known that cancer-associated DIC can be controlled by therapeutic-dose heparin. 20, 21 If our patients had had HIT we would have expected to see a platelet count fall with initiation of heparin. In addition, several of the patients had unexplained thrombocytopenia and/or
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Studies of available plasma samples support a model of disturbed procoagulantanticoagulant balance in the cases we report, as we have proposed in our previous studies of HIT-associated venous limb gangrene. [2] [3] [4] Similar to our previous reports, patients with cancerassociated venous limb ischemia exhibited the combination of a marked reduction in PC activity levels (generally, <0.10 U/mL) at a time when TAT levels were greatly elevated, during the time of maximal INR coinciding with development of severe venous limb ischemia/gangrene.
The results of plasma testing provide further insights into the explanation for the characteristic supratherapeutic INR in patients with warfarin-and cancer-associated venous limb ischemia. We found a strong association between PC activity levels and 1/INR, which supports a key pathophysiological role for severe depletion of PC activity levels in predisposing to microvascular thrombosis. However, PC activity levels do not influence the INR, so we examined factors that do affect the INR (VII, X, II, V) to explain variability in INR values, and parallel correlations with PC activity levels. In these analyses we showed strong correlations between factor VII and, to a lesser extent factor X, in predicting for an elevated INR. Indeed, in multivariate analyses, approximately 90% of the variability in 1/INR was explained by factor VII levels. Thus, given the highly collinear relationship between factor VII and PC activity levels (Ω 2 =81.9%) ( Figure 5B), our observations suggest that the supratherapeutic INR is a surrogate marker for severe depletion in PC activity levels which parallel severe depletion in factor VII levels, and to a lesser extent, factor X levels. Interestingly, factor II levels were generally much
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A clinical trial showed LMWH (dalteparin) was superior to warfarin in patients with cancer-associated DVT. 22 However, for 8 of our 10 patients, the diagnosis of cancer was not apparent at onset of venous limb ischemia. Indeed, the presenting clinical picture was that of "idiopathic" DVT, which was treated with a standard regimen of UFH or LMWH with overlapping warfarin therapy (mean 5-day overlap). Our patients' limb ischemia was not likely related to insufficient duration of overlap, as recurrent thrombocytopenia, DIC exacerbation, and DVT progression occurred even in patients who underwent a full 6-day overlap. Of note, some patients only developed venous limb gangrene when a second trial of warfarin therapy was attempted. Thus, we recommend that for a patient with warfarin failure who has evidence for DIC (and where underlying cancer might be present), that vitamin K antagonist therapy not be readministered, given the risk for devatastating limb loss. A limitation of our study was that cancer was not proven pathologically in 3 patients (as invasive diagnostic procedures were deemed inappropriate given the patients' terminal conditions).
In conclusion, our study points to warfarin therapy as being a key contributing factor in explaining the evolution of DVT to acral limb ischemia (phlegmasia) and venous limb gangrene in some patients with cancer-associated hypercoagulability. This disorder presents a striking clinical resemblance to HIT complicated by warfarin-induced venous limb gangrene, in which warfarin fails to inhibit thrombin generation while contributing to severe depletion in PC activity levels. However, in HIT the hypercoagulable state is the result of procoagulant effects of HIT antibodies, whereas in cancer-associated venous limb gangrene, the procoagulant effects are For personal use only. on August 16, 2017 . by guest www.bloodjournal.org From between factor VII and PC activity levels (see text for analyses, interpretation, and discussion). * Four patients were investigated for HIT antibodies because of thrombosis without thrombocytopenia. † Thrombotic events included DVT(s) (n=26), limb artery thrombosi(e)s (n=6), myocardial infarction (n=11), thrombotic cerebrovascular accident (n=5), and superior mesenteric artery thrombosis (n=1) (several patients had more than one thrombotic event). ‡ Symmetrical peripheral gangrene, i.e., bilateral lower limb gangrene despite palpable arterial pulses, was observed in a patient with septicaemia-associated DIC and hepatobiliary failure (obstructive jaundice secondary to nonresectable pancreatic cancer). § Miscellaneous categories include HIV-associated thrombocytopenia (n=1), lymphoma-associated hematophagocytosis (n=1), intracardiac tumor (n=1), and two patients with insufficient information available for classification. All 10 patients were diagnosed as having metastatic cancer. All 10 patients tested negative for HIT in the SRA; additionally, patients 1, 6, 7, 8, 9, and 10 tested negative in the IgG-specific PF4/heparin ELISA, whereas patient 4 tested positive by ELISA (but did not have HIT based upon the negative SRA and platelet count increase when UFH was restarted following the negative SRA test result. Only patient 3 tested strongly positive by PF4/heparin ELISA (3.24 units; normal <0.45 units), but the SRA was repeatedly negative, and cancer-associated DIC was judged a more probable diagnosis than HIT. No serum was available from patients 2 and 5 for testing in the PF4/heparin ELISA. * Diagnosis of cancer was not known or suspected at time of presentation of initial thrombosis. † Pathology was available and showed adenocarcinoma (except patient 5, which showed ovarian clear cell carcinoma). For patients 1, 7, and 10, for
